Acadian Asset Management LLC Makes New $1.77 Million Investment in Haleon PLC Sponsored ADR $HLN

Acadian Asset Management LLC purchased a new position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 171,950 shares of the company’s stock, valued at approximately $1,767,000.

Other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in Haleon by 6.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,223 shares of the company’s stock worth $306,000 after buying an additional 1,749 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Haleon by 11.2% during the first quarter. Oppenheimer & Co. Inc. now owns 25,362 shares of the company’s stock worth $261,000 after buying an additional 2,564 shares in the last quarter. Concurrent Investment Advisors LLC boosted its stake in Haleon by 32.9% during the first quarter. Concurrent Investment Advisors LLC now owns 16,363 shares of the company’s stock worth $168,000 after buying an additional 4,055 shares in the last quarter. Mather Group LLC. boosted its stake in Haleon by 60.7% during the first quarter. Mather Group LLC. now owns 9,036 shares of the company’s stock worth $93,000 after buying an additional 3,413 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its stake in Haleon by 264.6% during the first quarter. Baird Financial Group Inc. now owns 69,350 shares of the company’s stock worth $714,000 after buying an additional 50,328 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on HLN shares. Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday. BNP Paribas raised Haleon to a “strong-buy” rating in a report on Tuesday, May 27th. BNP Paribas Exane raised Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 price objective for the company in a report on Tuesday, May 27th. Wall Street Zen cut Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Finally, The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Stock Performance

Haleon stock opened at $9.27 on Wednesday. The stock has a 50-day simple moving average of $9.70 and a 200 day simple moving average of $10.19. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 12-month low of $8.86 and a 12-month high of $11.42. The stock has a market capitalization of $41.49 billion, a price-to-earnings ratio of 23.77, a P/E/G ratio of 2.86 and a beta of 0.24.

Haleon Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Thursday, September 18th. Investors of record on Friday, August 15th will be issued a $0.0555 dividend. This is a positive change from Haleon’s previous semi-annual dividend of $0.05. This represents a dividend yield of 190.0%. The ex-dividend date of this dividend is Friday, August 15th. Haleon’s dividend payout ratio (DPR) is presently 28.21%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.